Prostate Cancer
Risk group Low Intermediate High NCCN T-stage cT1c + cT2a and cT2b – 2c and/or cT3 or PSA <10 ng/ml and >10–20 ng/ml and/or >20 ng/ml or Gleason sum <7 =7 8–10…
ONCOLOGY
Gastric Cancer
Figs. 9.1 and 9.2 LN drainage: Compartment 1 (DI resection): 1. right cardial nodes; 2. left cardial nodes; 3. nodes along the lesser curvature; 4. nodes along the greater curvature;…
Central Venous Catheters: Care and Complications
Recommendation Level of evidencea Insertion Hand hygiene with soap and water or waterless alcohol gel 1A Maximal sterile barrier precautions: cap, mask, sterile gown, sterile gloves, sterile full body…
Oral Mouth Care and Mucositis
Therapy-related risk factors Chemotherapy and biotherapy agents Antimetabolites Cytarabine 5-fluorouracil Methotrexate Antitumor antibiotics Actinomycin D Amsacrine Mithramycin Mitomycin Alkylating agents Busulfan Cyclophosphamide Mechlorethamine Procarbazine Thiotepa Anthracyclines Daunorubicin Doxorubicin Epirubicin Taxanes…
Pain Management
Fig. 9.1 Pain assessment tools. (a) FLACC behavioral pain assessment scale. (b) Wong-Baker faces pain scale. (c) Visual analog scale (VAS) The perception of pain is directly related to a…
Neurologic Emergencies
Clinical scenario Recommendations Level of evidenceb Spinal cord compression Corticosteroids: decadron 1–2 mg/kg (max 10 mg) followed by 0.25–0.5 mg/kg (max 4 mg) Q6h—may complicate ability to make a diagnosis…
Febrile Neutropenia
Clinical scenario Recommendation Level of evidencea Risk stratification Must be individualized at local institutions due to lack of evidence to support the needs of each individual treatment area 2C Baseline…
Knowledge Gaps and Opportunities for Research
© Springer Berlin Heidelberg 2015James H. Feusner, Caroline A. Hastings and Anurag K. Agrawal (eds.)Supportive Care in Pediatric OncologyPediatric Oncology10.1007/978-3-662-44317-0_18 18. Knowledge Gaps and Opportunities for Research Anurag K. Agrawal1 , Caroline A. Hastings1 and James H. Feusner1 (1) Department of Hematology/Oncology, Children’s…
Immunization Practice in Pediatric Oncology
Prior to chemotherapyb During chemotherapyc After chemotherapy completionc, d Diphtheria-tetanus-acellular pertussis Continuation of primary series during lower-intensity phases of therapy (i.e., ALL in maintenance) Continuation of primary series; booster…
Hematopoietic Growth Factors
Clinical scenario Recommendation Level of evidenceb Treatment of myelosuppression after chemotherapy (primary prophylaxis) Consider if risk of neutropenia is ≥20 % or if patient had neutropenia with previous course of…
